Glycopyrronium Bromide Martindale Pharmaceuticals (Glycopyrronium Bromide)

Glycopyrronium bromide is employed in several clinical settings where reduction of secretions or bronchodilation is desired.

• Preoperative reduction of salivary, bronchial, and gastric secretions to facilitate anesthesia.
• Management of bronchospasm associated with chronic obstructive pulmonary disease (COPD).
• Adjunct therapy for asthma when other bronchodilators are insufficient.
• Treatment of excessive airway secretions in patients requiring mechanical ventilation.
• Use in diagnostic procedures where airway secretions may interfere with results.

Side effects of glycopyrronium bromide reflect its anticholinergic activity on muscarinic receptors.

Common

• Dry mouth (xerostomia).
• Throat irritation.
• Nasal dryness.
• Mild headache.
• Transient increase in heart rate.
• Flushing of the skin.

Serious

• Severe bronchospasm.
• Cardiac arrhythmias.
• Acute urinary retention.
• Vision disturbances such as blurred vision.
• Allergic reactions including rash, itching, or anaphylaxis.

When prescribing glycopyrronium bromide, clinicians should consider several safety factors.

• Assess patient history for glaucoma, urinary retention, or gastrointestinal obstruction.
• Use caution in patients with cardiovascular disease or tachyarrhythmias.
• Monitor for signs of excessive anticholinergic burden, especially in the elderly.
• Adjust dose or avoid use in patients with known hypersensitivity to glycopyrronium or related compounds.
• Evaluate renal and hepatic function, as impairment may affect drug clearance.
• Ensure appropriate timing relative to anesthesia to avoid prolonged secretory suppression.

Glycopyrronium bromide may interact with other medications that influence cholinergic pathways or cardiac function.

Avoid

• Other anticholinergic agents (e.g., atropine, scopolamine) that may amplify anticholinergic side effects.
• Drugs that prolong the QT interval when combined with significant tachycardia.

Use with caution

• Beta‑agonist bronchodilators, as combined effects on heart rate may occur.
• Medications that increase secretions, such as cholinesterase inhibitors.
• Drugs metabolized by hepatic enzymes that could be inhibited or induced, potentially altering glycopyrronium levels.
• Anesthetic agents that may synergize with anticholinergic effects on airway secretions.